Treatment decisions for Waldenstrom’s macroglobulinemia should consider comorbidities, lifestyle, and cost, as chemotherapy and BTK inhibitors show similar response rates. BTK inhibitors, including ...
Business Insider: Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression ...
Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression ...
Cure Today: Trial for Waldenstrom’s Macroglobulinemia Treatment Will Continue, as Early Data Yields Promising Results
CLR 131 shows promise in treating relapsed/refractory Waldenstrom’s macroglobulinemia, targeting B-cell malignancies with iodine-131 delivery. The trial will enroll 50 patients, administering up to ...
Trial for Waldenstrom’s Macroglobulinemia Treatment Will Continue, as Early Data Yields Promising Results
Seeking Alpha: Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
Nasdaq: Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
EurekAlert!: Researchers identify genetic mutation responsible for most cases of Waldenstrom's macroglobulinemia
SAN DIEGO—Scientists at Dana-Farber Cancer Institute have identified a gene mutation that underlies the vast majority of cases of Waldenstrom's macroglobulinemia, a rare form of lymphoma that has ...
Benzinga.com: Mustang Bio Shares Gain As FDA Grants Orphan Drug Status To Waldenstrom Drug